It doesn’t cure the life-sapping condition, but the Food and Drug Administration determined that its ability to reduce clumps of plaque in the brain is likely to slow dementia. “We simply cannot wait any longer to provide real relief to seniors.” Pallone has been a proponent of the original House version of the legislation, which took a tougher approach toward the pharmaceutical industry.Īlzheimer’s is a progressive neurological disease with no known cure, affecting about 6 million Americans, the vast majority old enough to qualify for Medicare.Īduhelm is the first Alzheimer’s medication in nearly 20 years. Frank Pallone, D-N.J., said in a statement. confirms the need for Congress to finally give Medicare the ability to negotiate lower prescription drug costs,” Rep. The news on Medicare premiums could reopen that debate internally among Democrats. However, under the latest compromise, Medicare would not be able to negotiate prices for newly launched drugs. The late Friday afternoon announcement - in a time slot government agencies use to drop bad news - comes as Congress is considering Democratic legislation backed by President Joe Biden that would restrain what Medicare pays for drugs. Officials said the other half of the premium increase is due to the natural growth of the program and adjustments made by Congress last year as the coronavirus pandemic hit. “The increase in the Part B premium for 2022 is continued evidence that rising drug costs threaten the affordability and sustainability of the Medicare program,” said Medicare chief Chiquita Brooks-LaSure in a statement. As recently as August, the Medicare Trustees’ report had projected a smaller increase of $10 from the current $148.50.
The jump of $21.60 is the biggest increase ever in dollar terms, although not percentage-wise.
The new Part B premium will be $170.10 a month for 2022, officials said. People who don’t have Alzheimer’s would not be shielded from the cost of Aduhelm, since it’s big enough to affect their premiums. The issue is turning into a case study of how one pricey medication for a condition afflicting millions of people can swing the needle on government spending and impact household budgets. The medication would add to the cost of outpatient coverage because it’s administered intravenously in a doctor’s office and paid for under Part B.
Medicare officials told reporters on Friday that about half the increase is due to contingency planning if the program ultimately has to cover Aduhelm, the new $56,000-a-year medication for Alzheimer’s disease from pharmaceutical company Biogen. The increase guarantees that health care will gobble up a big chunk of the recently announced Social Security cost-of-living allowance, a boost that had worked out to $92 a month for the average retired worker, intended to help cover rising prices for gas and food that are pinching seniors. Officials said Friday a new Alzheimer’s drug is responsible for about half of that. WASHINGTON (AP) - Medicare’s “Part B” outpatient premium will jump by $21.60 a month in 2022, one of the largest increases ever.
0 kommentar(er)
